Chronic granulocytic leukemia can be divided into chronic phase, accelerated phase and acute phase, and the specific survival time varies and needs to be analyzed according to the disease. Chronic granulocytic leukemia is a myeloproliferative disease that can be diagnosed clinically through peripheral blood tests and genetic testing that reveals abnormalities in blood cells, the Philadelphia chromosome and the bcr/abl fusion gene. Patients in the chronic phase will also present with fever and malaise. It is generally not life threatening and this phase can last about 10 years and the chronic phase about 3 years. Patients with accelerated-phase slow-onset granulocytosis may present with fever, anemia, bleeding, infection, weight loss, malaise, and hepatosplenomegaly, and the lesions may last about six months to a year. Acute stage slow-onset granulocytosis is the end-state of the disease, and patients have a poor prognosis and may lose their lives in a few months. The median 5-year survival rate for chronic granulocytic leukemia is 25%-35%. However, since the introduction of TKI (tyrosine kinase inhibitors), the prognosis has greatly improved and most patients do not require stem cell transplantation and can achieve long-term survival on oral medications alone. Patients are advised to consult the hematology department promptly in case of discomfort, seek early emergency care, and actively take appropriate treatment for maximum survival.